Acme United (ACU) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales increased 4% to $55.4 million, with net income up 29% to $4.5 million and EPS up 14% to $1.09 per share; excluding divested lines, organic sales grew 8%.

• The Elite First Aid acquisition in May 2024 for $6.1 million expanded the first aid and emergency response product portfolio and customer base.

• Gross margin improved to 40.8% in Q2 2024 from 37.5% a year ago, driven by productivity gains.

• The company completed the sale of Camillus and Cuda product lines in November 2023, generating $13.0 million in net proceeds used to pay down debt and fund growth.

• Integration of Hawktree Solutions in Canada is progressing, showing positive momentum after restructuring.

Financial highlights

• Q2 2024 net sales: $55.4 million (Q2 2023: $53.3 million); six-month sales: $100.4 million (2023: $99.2 million).

• Q2 2024 net income: $4.5 million (Q2 2023: $3.4 million); six-month net income: $6.1 million (2023: $4.4 million).

• Q2 2024 operating income: $6.4 million (Q2 2023: $5.3 million); six-month operating income: $8.9 million (2023: $7.4 million).

• Diluted EPS for Q2 2024: $1.09 (Q2 2023: $0.96); six-month diluted EPS: $1.47 (2023: $1.25).

• Interest expense, net, decreased to $539,000 in Q2 2024 from $832,000 in Q2 2023.

Outlook and guidance

• Management expects continued organic growth, leveraging the Elite First Aid acquisition to expand offerings and customer reach, and is evaluating further acquisitions.

• SG&A as a percentage of sales is expected to decline slightly for the year, with some increases due to bonuses and IT investments.

• Gross margin is expected to remain stable, with a tendency to increase as higher-margin first aid products grow.

• Management anticipates sufficient liquidity for operations over the next twelve months, supported by cash flow and available credit.

• Seasonal strength is expected in Q3 due to the back-to-school market.